The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Mar. 31, 2015
Filed:
Nov. 11, 2011
Applicant:
Shi Yin Foo, Brookline, MA (US);
Inventor:
Shi Yin Foo, Brookline, MA (US);
Assignee:
Novartis AG, Basel, CH;
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/16 (2006.01); A61K 31/04 (2006.01); A61K 31/5375 (2006.01); A61K 31/192 (2006.01); A61K 31/194 (2006.01); A61K 31/198 (2006.01); A61K 31/216 (2006.01); A61K 31/235 (2006.01); A61K 31/335 (2006.01); A61K 31/34 (2006.01); A61K 31/341 (2006.01); A61K 31/343 (2006.01); A61K 31/35 (2006.01); A61K 31/357 (2006.01); A61K 31/381 (2006.01); A61K 31/40 (2006.01); A61K 31/4045 (2006.01); A61K 31/41 (2006.01); A61K 31/415 (2006.01); A61K 31/4164 (2006.01); A61K 31/4184 (2006.01); A61K 31/4196 (2006.01); A61K 31/42 (2006.01); A61K 31/421 (2006.01); A61K 31/4245 (2006.01); A61K 31/44 (2006.01); A61K 31/4402 (2006.01); A61K 31/445 (2006.01); A61K 31/505 (2006.01); A61K 31/513 (2006.01); A61K 45/06 (2006.01); A61K 31/197 (2006.01); C07C 235/06 (2006.01); C07C 235/74 (2006.01); C07C 235/82 (2006.01); C07C 275/24 (2006.01); C07D 207/16 (2006.01); C07D 213/56 (2006.01); C07D 213/76 (2006.01); C07D 231/14 (2006.01); C07D 231/20 (2006.01); C07D 235/16 (2006.01); C07D 239/28 (2006.01); C07D 239/34 (2006.01); C07D 249/12 (2006.01); C07D 257/04 (2006.01); C07D 261/18 (2006.01); C07D 263/34 (2006.01); C07D 271/113 (2006.01); C07D 307/68 (2006.01); C07D 317/40 (2006.01);
U.S. Cl.
CPC ...
A61K 31/5375 (2013.01); A61K 31/192 (2013.01); A61K 31/194 (2013.01); A61K 31/198 (2013.01); A61K 31/216 (2013.01); A61K 31/235 (2013.01); A61K 31/335 (2013.01); A61K 31/34 (2013.01); A61K 31/341 (2013.01); A61K 31/343 (2013.01); A61K 31/35 (2013.01); A61K 31/357 (2013.01); A61K 31/381 (2013.01); A61K 31/40 (2013.01); A61K 31/4045 (2013.01); A61K 31/41 (2013.01); A61K 31/415 (2013.01); A61K 31/4164 (2013.01); A61K 31/4184 (2013.01); A61K 31/4196 (2013.01); A61K 31/42 (2013.01); A61K 31/421 (2013.01); A61K 31/4245 (2013.01); A61K 31/44 (2013.01); A61K 31/4402 (2013.01); A61K 31/445 (2013.01); A61K 31/505 (2013.01); A61K 31/513 (2013.01); A61K 45/06 (2013.01); A61K 31/197 (2013.01); C07C 235/06 (2013.01); C07C 235/74 (2013.01); C07C 235/82 (2013.01); C07C 275/24 (2013.01); C07D 207/16 (2013.01); C07D 213/56 (2013.01); C07D 213/76 (2013.01); C07D 231/14 (2013.01); C07D 231/20 (2013.01); C07D 235/16 (2013.01); C07D 239/28 (2013.01); C07D 239/34 (2013.01); C07D 249/12 (2013.01); C07D 257/04 (2013.01); C07D 261/18 (2013.01); C07D 263/34 (2013.01); C07D 271/113 (2013.01); C07D 307/68 (2013.01); C07D 317/40 (2013.01);
Abstract
The present invention provides the use of a neutral endopeptidase inhibitor, in the manufacture of a medicament for the treatment, amelioration and/or prevention of contrast-induced nephropathy. The invention also relates to the use of a compound of Formula I: wherein R, R, R, R, X, A, B, s and n are defined herein, for the treatment, amelioration and/or prevention of contrast-induced nephropathy. The present invention further provides a combination of pharmacologically active agents for use in the treatment, amelioration and/or prevention of contrast-induced nephropathy.